BioSpace News Archive

Genetown

Anokion Announces $35 Million Equity Investment from Pfizer

Anokion SA , a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Pfizer has made a $35 million equity investment in Anokion through the Pfizer Breakthrough Growth Initiative.

October 18, 2022
·
3 min read
Business

Foldax Appoints Gregory D. Casciaro as Chief Executive Officer

Foldax ® , Inc. today announced that medtech veteran Gregory D. Casciaro has been named Chief Executive Officer of the company, effective yesterday.

October 18, 2022
·
2 min read
Business

Apollo Endosurgery to Report Third Quarter Results on November 1, 2022

Apollo Endosurgery, Inc. today announced that the Company is scheduled to release financial results for the third quarter ended September 30, 2022 on Tuesday, November 1, 2022, after market close.

October 18, 2022
·
2 min read
Pharm Country

Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease

Teva Announces Results from 3-Year Study Assessing the Safety and Tolerability of AUSTEDO ® (deutetrabenazine) Tablets for the Treatment of Chorea Associated with Huntington’s Disease.

October 18, 2022
·
13 min read
Drug Development

LENZ Therapeutics Announces Positive Topline Data from Phase 2 INSIGHT Trial of LNZ100 and LNZ101 to Treat Presbyopia

LENZ Therapeutics, a privately held late-stage clinical company, today reported positive topline results from its Phase 2 INSIGHT clinical trial of two investigational formulations of aceclidine to treat presbyopia.

October 18, 2022
·
4 min read
Biotech Beach

TAE Life Sciences to Sponsor Industry Theater Session on the Future of Precision Oncology at 2022 ASTRO Annual Meeting

TAE Life Sciences today announced the sponsorship of an Industry Education session focused on the future of biologically targeted radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting.

October 18, 2022
·
3 min read
Drug Development

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1)

Cyclo Therapeutics Announces Publication of Phase 1 Data for Trappsol ® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1 (NPC1).

October 18, 2022
·
7 min read
Drug Development

Salarius Pharmaceuticals Announces Pause in New Patient Enrollment in its Phase 1/2 Trial of Seclidemstat in Ewing Sarcoma and FET-Rearranged Sarcomas

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that, as per protocol design, it is voluntarily pausing new patient enrollment in the company’s Phase 1/2 trial of seclidemstat as a treatment for Ewing sarcoma and FET-rearranged sarcomas.

October 18, 2022
·
7 min read
VectivBio Announces Closing of $125 Million Underwritten Offering of Ordinary Shares

VectivBio Holding AG announced the closing of its previously announced underwritten offering of 16,700,000 ordinary shares at an offering price of $7.50 per share.

October 18, 2022
·
4 min read
Business

Blue Earth Diagnostics Announces Data-sharing Agreement with Siemens Healthineers and the University Hospital of Technical University of Munich (TUM) for 18F-rhPSMA-7.3

Blue Earth Diagnostics today announced the signing of a data-sharing agreement with Siemens Healthineers and the University Hospital of the Technical University of Munich (TUM) for anonymized 18 F-rhPSMA-7.3 clinical data and images.

October 18, 2022
·
6 min read